Author

Laura Barnabei

Institute of Oncology Research

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Alberto J. ArribasiD· 1 shared Anastasios StathisiD· 1 shared Andrea RinaldiiD· 1 shared Chiara TarantelliiD· 1 shared Davide RossiiD· 1 shared Eleonora CannasiD· 1 shared Elisa CivanelliiD· 1 shared Emanuele ZuccaiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alberto J. ArribasORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models

Laura Barnabei, Alberto J. Arribas, Luciano Cascione, Gabriela Forestieri, Eleonora Cannas, Francesca Guidetti, Filippo Spriano, Elisa Civanelli, Chiara Tarantelli, Samuele Di Cristofano, Stefano Raniolo, Andrea Rinaldi, Anastasios Stathis, Davide Rossi, Emanuele Zucca, , Francesco Bertoni

This study shows that combining CXCR4 inhibitors with standard and targeted therapies improves anti-tumor effects in B-cell lymphoma models, especially in drug-resistant cases.

bioRxiv · Jul 10, 2025 · PreprintCancer Biology